A Switch That Keeps Cancer-Fighting Immune Cells From Burning Out

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have found a molecular switch that pushes cancer-fighting immune cells into exhaustion — and flipping it off kept engineered cancer-fighting immune cells attacking tumors for longer in laboratory and mouse experiments. The finding, reported in the journal Cancer Immunology Research, points toward a new way to make immunotherapies last in solid tumors, the cancers where treatments such as CAR-T cells most often fade too quickly. According to the MedicalXpress report on the study, blocking the pathway allowed immune cells to stay active longer and resist exhaustion in preclinical models.

To hunt for the genes behind that fade-out, the UCLA team ran a genome-wide CRISPR screen in human CD8 T cells engineered to recognize a melanoma antigen. They systematically switched off thousands of genes and then exposed the cells to tumor cells again and again, in a laboratory system designed to mimic the chronic, repeated tumor exposure that immune cells face inside patients with solid tumors. The goal was to learn what makes cancer-fighting immune cells give up — and how to stop it. The screen kept pointing to the same culprit: a protein-regulating pathway called the Cullin-5 RING E3 ligase complex, or CRL5, which helps cells break down and recycle proteins. It was not a single gene that stood out — several different components of the CRL5 machinery were independently enriched across experiments and time points, a pattern that usually signals a biologically important pathway.

Why exhaustion is the enemy

T-cell exhaustion is one of the main reasons many immunotherapies stop working or never produce lasting responses. T cells are the immune system's primary cancer-fighting cells, but in many cancers they sit in a tumor's chemical crossfire for months, gradually losing their ability to recognize and kill cancer cells. The problem hits hardest in solid tumors, where CAR-T cells, tumor-infiltrating lymphocyte therapies, and T-cell receptor-engineered therapies all struggle to stay effective over time. Keeping cancer-fighting immune cells in the fight longer is the central challenge of modern cell therapy, and prevention research is advancing on other fronts too — bariatric surgery has been linked to lower cancer risk across ages and sexes.

"Immunotherapy depends on T cells staying active long enough to continuously recognize and kill cancer cells," said Justin Saco, a graduate student in the laboratory of Dr. Antoni Ribas at UCLA and the study's first author, in the report. "If they lose function too early, tumors can grow back or escape immune control. The longer T cells remain functional, the better the chance of durable cancer control." His team's approach stood out because most exhaustion research studies short bursts of activation. "Instead of studying short-term T-cell activation, we modeled the chronic, repeated tumor exposure that T cells experience in solid tumors," Saco said. "That allowed us to identify regulators of long-term persistence and exhaustion more effectively."

What changed when the pathway was blocked

When the researchers disrupted genes tied to the CRL5 machinery, the modified cancer-fighting immune cells held onto their tumor-killing ability through repeated exposure. They produced higher levels of immune signaling molecules, showed fewer molecular signs of exhaustion, and preserved gene programs linked to survival and long-term immune function. The team also tested a drug that blocks activation of Cullin-RING ligases, including CRL5. The drug partially reproduced the effects of deleting the genes, helping T cells maintain stronger long-term function in laboratory experiments.

The strongest signal came from animal tests. In mouse models of human melanoma, animals treated with CRL5-deficient T cells showed improved tumor control compared with those that received standard engineered immune cells. And the result was not a one-lab fluke: a companion research article in the same journal, from the group of Dr. Julia Carnevale at UCSF, independently found that disrupting the same protein complex enhances engineered T-cell persistence under chronic tumor exposure.

Promising, but still preclinical

There are reasons to keep expectations measured. Everything so far comes from cell cultures and mouse models, and those results do not always translate to people. The tested drug only partially reproduced the genetic effect, which means a future therapy would need a more precise way to target the pathway without disrupting protein recycling elsewhere in the body. The researchers describe the work as a starting point for developing longer-lasting immunotherapies, not a treatment that is ready for trials.

Still, the direction matters for anyone watching cancer care. Solid tumors make up the vast majority of cancers, and the field's biggest frustration has been that engineered cell therapies work brilliantly in some blood cancers and then run out of steam against solid masses. If a druggable exhaustion switch works the same way in patients, oncologists could one day engineer cancer-fighting immune cells that simply refuse to quit — turning short-lived responses into durable ones. Two independent teams landing on the same pathway at the same time is the kind of convergence that tends to attract serious follow-up funding, so this is a story worth watching well beyond the lab, especially as cancers once considered diseases of older adults keep appearing in younger patients.